Cytek Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
Cytek Biosciences, Inc. filed a Form 8-K reporting the results of its 2022 annual meeting of stockholders, held June 1, 2022. The report was signed and filed June 6, 2022. The company’s common stock trades on the Nasdaq Global Select Market under the symbol CTKB.
As of the April 4, 2022 record date, 134,242,304 shares were outstanding. A total of 115,966,354 shares, approximately 86% of the shares entitled to vote, were represented at the meeting.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial performance metrics.
Material Changes Versus the Prior Comparable Period
The filing does not report financial or operating changes versus a prior comparable period.
Both Class I director nominees were elected to serve until the 2025 annual meeting or until their successors are elected and qualified.
| Director | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Deborah Neff | 88,739,812 | 609,979 | 26,616,563 |
| Don Hardison | 88,652,419 | 697,372 | 26,616,563 |
Stockholders ratified the selection of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.
| Vote | Shares |
|---|---|
| For | 115,377,037 |
| Against | 5,450 |
| Abstentions | 583,867 |
| Broker Non-Votes | None |
Guidance, Outlook, Risks, and Unusual Items
The filing provides no management guidance, outlook, material risk updates, contingencies, or unusual financial items. It indicates that Cytek is an emerging growth company.
Key Facts for Investors to Verify
- Confirm the election and terms of Deborah Neff and Don Hardison as Class I directors.
- Confirm Deloitte & Touche LLP’s ratification for the fiscal year ending December 31, 2022.
- Review the company’s other filings for financial performance, liquidity, debt, guidance, and risk disclosures, which are not included in this 8-K.
- Note the distinction between the June 1 meeting date and the June 6 filing signature date.